UNSPSC 51142557: Memantine hydrochloride

This classification denotes an antiparkinsonian agent with the molecular formula C12H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JY0WD0UA60, chemically known as 3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine but more generally known as memantine hydrochloride, which bears US NIH Compound Identifier 4054. European Medicines Agency schedules Memantine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03137MIG.

Most nations, for tariff and trade purposes, schedule memantine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, MEMANTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Memantine hydrochloride bears US NLM identifiers UMLS ID C0771988 and NCI Concept Code C47601. SMILES: C[C@@]12CC3C[C@@](C1)(C[C@](C3)(C2)N)C.CL.

UNSPSC 51142557 Memantine hydrochloride, a Commodity code, shows limited recent state and local procurement activity that directly aligns with the code's pharmaceutical scope. The single recent opportunity identified—Seminole County, Florida's IFB 60459723LAS—was actually for naloxone and drug deactivation systems, not memantine, indicating a mismatch between the code assignment and the work being solicited. State and local governments use this code to procure memantine hydrochloride, a medication commonly used in the treatment of moderate to severe Alzheimer's disease, typically through health departments, county health systems, or social services agencies managing long-term care and senior health programs. When correctly applied, purchasing activity under this code reflects demand from public health agencies, state Medicaid programs, Veterans Affairs affiliates, and institutional care facilities that stock pharmaceutical inventory for eligible populations.

The geographic and issuing-body profile remains unclear from current sourced activity. Seminole County's recent bid for naloxone and deactivation systems does not provide a reliable signal for memantine procurement patterns or regional concentration. The code shows minimal recent state and local contract posting visibility, suggesting either light current demand in the posted-opportunity channel or that memantine purchases are frequently consolidated under broader pharmaceutical supply agreements, cooperative purchasing frameworks, or state-level health department contracts that do not appear in the recent-opportunities sample. Firms pursuing memantine sales to state and local governments should monitor county health department RFPs, state Medicaid managed-care procurement cycles, and regional health system cooperative-purchasing vehicles for demand signals.